MedTrace Logo

Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With COVID-19

NCT04252118 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2020-04-15

No results posted yet for this study

Summary

The SARS-CoV-2 infection caused clusters of severe respiratory illness similar to severe acute respiratory syndrome coronavirus and was associated with ICU admission and high mortality. There is no confirmed antivirus therapy for people infected SARS-CoV-2, most of them should receive supportive care to help relieve symptoms. For severe cases, treatment should include care to support vital organ functions. This clinical trial is to inspect the safety and efficiency of Mesenchymal Stem Cells (MSCs) therapy for pneumonia patients infected with SARS-CoV-2.

Conditions

Interventions

BIOLOGICAL

MSCs

3 times of MSCs(3.0\*10E7 MSCs intravenously at Day 0, Day 3, Day 6).

Sponsors & Collaborators

  • Innovative Precision Medicine Group (IPM), Hangzhou, China.

    collaborator UNKNOWN

  • Huoshenshan Hospital

    collaborator OTHER

  • Tianjin Haihe Hospital

    collaborator OTHER

  • Vcanbio Cell and Gene Engineering Corp., Ltd.

    collaborator INDUSTRY

  • Shenzhen Third People's Hospital

    collaborator OTHER

  • Fifth Affiliated Hospital, Sun Yat-Sen University

    collaborator OTHER

  • Beijing 302 Hospital

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-27
Primary Completion
2020-12-31
Completion
2021-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04252118 on ClinicalTrials.gov